e., acenocoumarol). The characteristics of patients according to whether or not they received PF-573228 purchase rifampicin are shown in Table 2. Although no difference between both groups was statistically significant, patients receiving rifampicin

had a higher rate of diabetes mellitus (27% vs. 18%), a longer MK-0457 mw duration of symptoms before open debridement (9 vs. 2 days), and all MRSA infections were recorded in the rifampicin group (5 vs. 0). The remission rate was lower in the rifampicin group (64% vs. 82%, P = 0.28) due to a higher relapse rate (27% vs. 12%). There were 9 infections due to Staphylococcus aureus, 8 cases (including the 5 MRSA infections in the rifampicin group) were considered in remission (89%) ABT-263 concentration and 1 patient had a new infection. In contrast, 15 out of 26 infections were due to coagulase-negative staphylococci.

Table 2 Characteristics of patients receiving or not rifampicin concomitantly with linezolid Characteristics Receiving rifampicin (n = 22) Not receiving rifampicin (n = 17) P Median (IQR) age 71 (63–75) 75 (66–77) 0.31 Male sex (%) 9 (41) 9 (53) 0.45 Diabetes mellitus (%) 6 (27) 3 (18) 0.37 Type of implant (%)     0.50  Hip prosthesis 7 (32) 6 (35)    Knee prosthesis 15 (68) 10 (59)    Shoulder prosthesis – 1 (6)   Age of prosthesis 30 (21–55) 24 (17–32) Quisqualic acid   Late acute infections (%) 2 (9) 2 (12) 1 Median (IQR) days of symptoms before debridement 9 (3–25) 2 (1–22) 0.14 Fever (%) 3 (14) 2 (12) 1 Bacteremia (%) 2 (9) 1 (6) 1 Median (IQR) leukocyte count (cells/mm3) 8,400 (6,400–9,600)

6,950 (5,750–8,125) 0.18 Median (IQR) C-reactive protein (mg/dL) 4 (2–11) 3 (1–5) 0.22 Microorganisms  S. aureus (MR) 6 (5) 3 (0)    CoNS (MR) 18 (13) 15 (10)    E. faecalis 3 1    S. viridans 1 1    Enterobacteriaceae 2 3  P. aeruginosa 1 – Polymicrobial (%) 9 (41) 6 (35) 0.50 Adverse events 9 (41) 8 (47)    Gastrointestinal (nausea, vomits or diarrhea) 7 (32) 3 (18)a    Hematological toxicity 1 (5) 4 (24)    Peripheral neuropathyb 1 (5) 1 (6)   Outcome (%)  Remission 14 (64) 14 (82) 0.28  Relapse 6 (27) 2 (12)    New infection 2 (9) 1 (6)    Median (IQR) days of follow-up from stopping antibiotics to the last visit 730 (161–1,219) 812 (618–1,362) 0.